News

Fierce Pharma2d
Bayer gains key FDA expansion for fast-rising prostate cancer drug Nubeqa
Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, ...
Fierce Pharma3d
ASCO: J&J's Akeega gives PARP a novel prostate cancer win, but FDA path in patient subset unclear
The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC) ...